A. Worobec

发表

Regulatory Issues Affecting Tumor Vaccines

R. Puri, K. Wonnacott, M. Thornton, 2004 .

Pharmacogenetics and Pharmacogenomics in Drug Development and Regulatory Decision Making: Report of the First FDA‐PWG‐PhRMA‐DruSafe Workshop

Shiew-Mei Huang, L. Lesko, A. Dorner, 2003, Journal of clinical pharmacology.

Treatment of systemic mast cell disorders.

A. Worobec, 2000, Hematology/oncology clinics of North America.

Mastocytosis: magnetic resonance imaging patterns of marrow disease

D. Metcalfe, N. Avila, A. Ling, 1998, Skeletal Radiology.

The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis.

B. Zweiman, D. Metcalfe, K. Sakai, 1995, The Journal of clinical investigation.

Mastocytosis: Current Treatment Concepts

D. Metcalfe, A. Worobec, 2002, International Archives of Allergy and Immunology.

Mastocytosis Complicating Pregnancy

L. Scott, D. Metcalfe, C. Akin, 2000, Obstetrics and gynecology.

Dangers of non-sedating antihistamines

P. Honig, A. Worobec, M. Himmel, 1997, The Lancet.

Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease.

L. Scott, D. Metcalfe, K. Brockow, 2002, Archives of dermatology.

Cushing's syndrome induced by betamethasone nose drops. Children taking intranasal corticosteroids should be monitored for growth retardation.

M. Purucker, S. Malozowski, A. Worobec, 1999, BMJ.

Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy

M. Atkins, J. Kirkwood, V. Maino, 2002, Journal of immunotherapy.

Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology.

L. Scott, D. Metcalfe, L. Schwartz, 2000, Blood.

Clinical correlates of the presence of the asp816Val c‐kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis

D. Metcalfe, T. Semere, A. Worobec, 1998, Cancer.

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.

Y. Suzuki, D. Metcalfe, S. Tannenbaum, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Treatment of three patients with systemic mastocytosis with interferon alpha-2b.

D. Metcalfe, L. Schwartz, D. Metcalfe, 1996, Leukemia & lymphoma.

Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis.

L. Scott, D. Metcalfe, C. Akin, 2000, Experimental hematology.

A risk-based approach to immunogenicity concerns of therapeutic protein product, Pat III

A. Rosenberg, Amy S. Rosenberg, Alexandra S. Worobec, 2004 .

A risk-based approach to immunogenicity concerns of therapeutic protein products: Part 2. Considering host-specific and product-specific factors impacting immunogenicity

A. Rosenberg, Amy S. Rosenberg, Alexandra S. Worobec, 2004 .

The protooncogene c-kit and c-kit ligand in human disease.

D. Metcalfe, H. Vliagoftis, D. Metcalfe, 1997, The Journal of allergy and clinical immunology.

Regression of urticaria pigmentosa in adult patients with systemic mastocytosis: correlation with clinical patterns of disease.

L. Scott, D. Metcalfe, K. Brockow, 2002, Archives of dermatology.

Inhibition of human mast cell growth and differentiation by interferon gamma-1b.

D. Metcalfe, T. Davis, J. Goff, 1998, Experimental hematology.